In an equity market that's starting to look expensive, are these three stocks still a good value?
From 100 hand-tied red roses to letter-box friendly bunches, these are the best flowers to order this Valentine's Day.
Thais flocked to a cannabis exhibition as interest and demand in the plant surges after the government unlocked hemp use in food and cosmetics in the latest move to promote a new cash crop. The government held a convention in Buriram province in northeastern Thailand over the weekend to educate the public on cannabis use and promote businesses. Hemp plants are a variety of cannabis that have higher concentrations of CBD, the non-psychoactive ingredient in marijuana, and lower levels of tetrahydrocannabinol (THC).
Eventbrite, Inc. (NYSE: EB), a global self-service ticketing and experience technology platform, today announced its intention to offer, subject to market and other conditions, $185 million aggregate principal amount of convertible senior notes due 2026 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Eventbrite also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 30 days from, and including, the date the notes are first issued, up to an additional $27.75 million aggregate principal amount of notes solely to cover overallotments, if any.
The "The Construction Industry in Angola 2020" report has been added to ResearchAndMarkets.com's offering.
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:CANACCORD GENUITY WEALTH LIMITED (for Discretionary Clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeSCAPA GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:N/A(e) Date position held/dealing undertaken: For an opening position disclosure, state the latest practicable date prior to the disclosure05 MARCH 2021(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”N/A 2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security. (a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any) Class of relevant security: ORDINARY 5p InterestsShort positionsNumber%Number%(1) Relevant securities owned and/or controlled:2,791,7131.4860 (2) Cash-settled derivatives: (3) Stock-settled derivatives (including options) and agreements to purchase/sell: TOTAL:2,791,7131.4860 Note: 2,500 shares were transferred out by a discretionary client on 03/03/2021. All interests and all short positions should be disclosed. Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions). (b) Rights to subscribe for new securities (including directors’ and other employee options) Class of relevant security in relation to which subscription right exists: Details, including nature of the rights concerned and relevant percentages: 3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in. The currency of all prices and other monetary amounts should be stated. (a) Purchases and sales Class of relevant securityPurchase/sale Number of securitiesPrice per unitORDINARY 5pSALE32,650214p (b) Cash-settled derivative transactions Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unitNONE (c) Stock-settled derivative transactions (including options) (i) Writing, selling, purchasing or varying Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unitNONE (ii) Exercise Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit (d) Other dealings (including subscribing for new securities) Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)NONE 4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none” NONE (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none” NONE (c) Attachments Is a Supplemental Form 8 (Open Positions) attached?NO Date of disclosure:08 MARCH 2021Contact name:MARK ELLIOTTTelephone number:01253 376539 Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.
TORONTO, March 08, 2021 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, is pleased to announce its wholly owned subsidiary, MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”), has entered into a new GMP white-label supply and contract manufacturing agreement with Cannim Australia Pty Ltd (“Cannim”). The Company also announced it has commenced registrations for the launch of next generations over-the-counter (“OTC”) products in Australia in 2021. “We are excited to partner with Cannim as the demand for high quality and novel formulations for cannabis products continues to rise along with Australia’s growing approved patient population,” said Keith Strachan, President and Interim CEO, MediPharm Labs. “As the go-to provider for new pharmaceutical and health and wellness companies entering the market in Australia, we are realizing the competitive advantage of our GMP-certified manufacturing capabilities and distribution channels to execute on our pipeline of opportunities to win new business.” Under the three-year agreement, with options to extend, MediPharm Labs Australia will supply a full range of specially formulated CBD and THC cannabis oil products that will be sold initially under Cannim’s Lumir brand. MediPharm Labs Australia will also provide Cannim with contract manufacturing with their starting material. John Worton, Founder of Cannim, said “We are delighted to have found a partner here in Australia with the capability to manufacture our GACP Jamaican Medicinal Cannabis into high quality, EU GMP standard finished products that can be sold both in Australia and internationally. Our first batch of Lumir tinctures produced at MediPharm Labs will be on sale in Australia this week, with more product for other markets to quickly follow.” Over-the-Counter Products Legalization in Australia As a GMP certified platform, MediPharm qualifies to launch the next generation of CBD products that will be available to all 5700 pharmacies across Australia to sell direct-to-consumers without a prescription. MediPharm has commenced its product registration process following the Therapeutic Goods Administration (“TGA”) re-scheduling of CBD in Australia in February 2021. This change in legislation is expected to grow the demand and market size for CBD products in Australia. All OTC products must be manufactured under GMP. “We are optimistic about our potential in 2021 for many good reasons including regulatory advancements,” said Keith Strachan, President and Interim CEO, MediPharm Labs. “In Australia, the TGA recently reclassified low dosage CBD (150 mg a day) – from Schedule 4 or prescription only to Schedule 3. This means successfully registered cannabis can be sold over the counter. Additionally, TGA has sought industry feedback on the regulation of medicinal cannabis. Proposed reforms include introducing equivalent GMP requirements for imported medicinal cannabis to Australia. The MediPharm team has been instrumental in driving these proposed reforms with a goal to enhance the quality and safety of medicinal cannabis.” “MediPharm Labs Australia is perfectly positioned to begin manufacturing and fulfilling the demand for this new OTC segment,” said Warren Everitt, CEO Asia Pacific, MediPharm Labs. “We have already seen interest from pharmaceutical companies looking for a GMP certified partner to comply with the TGA minimum requirements and execute on this new growth category.” About Cannim Based in Sydney, Australia, Cannim was established in 2017 to bring the benefits of medicinal cannabis to the world. Cannim operates farms in Jamaica and Australia, has established a network of EU GMP manufactures and alliances, delivering a range of branded products to bring relief in many forms to people across the world. Cannim continues to create scale in its operations, to meet the needs of the ever-growing body of medicinal cannabis users. Cannim is pioneering the development of the category, creating new ways for patients to effectively absorb its products, leading research into the effects of cannabis on a variety of conditions, pioneering its usefulness for others, and ensuring those in need get what they need when they need it at a price that’s fair. About MediPharm Labs Corp. Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical quality cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard built clean rooms. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision -dosed cannabis products for its customers. Through its wholesale and white label platforms, they formulate, consumer-test, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, MediPharm Labs has completed commercial exports to Australia and has fully commercialized its wholly-owned Australian extraction facility. MediPharm Labs Australia was established in 2017. CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: the demand for high quality and novel formulations for cannabis products rising; Australia’s approved patient population growing; realizing the competitive advantage of the Company’s GMP-certified manufacturing capabilities and distribution channels; executing on the Company’s pipeline of opportunities to win new business; growth in the demand and market size for CBD products in Australia; optimism about the Company’s potential in 2021; regulatory advancements; proposed reforms to cannabis regulations in Australia; enhancing the quality and safety of medicinal cannabis; the Company beginning the manufacturing and fulfillment of the demand for the new OTC segment; potential partnerships with pharmaceutical companies; and execution on a new growth category. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs’ filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change. All information contained in this press release with respect to Cannim was supplied by Cannim for inclusion herein. CONTACT: For further information, please contact: Laura Lepore, VP, Investor Relations Telephone: 705-719-7425 ext 1525 Email: email@example.com Website: www.medipharmlabs.com
A snapshot of a comet carrying carbon as it zipped past Earth in 2016 is helping NASA learn more about the origins of life.
Davina McCall: Sex, Myths And The Menopause will be broadcast on Channel 4 in the spring.
Global Blue today announced the acquisition of ZigZag, a leading Software-as-a-Service (SaaS) technology platform that helps retailers manage worldwide e-commerce returns and exchanges more profitably, and consumers to enjoy a smoother and enhanced return experience.
Airlines gave travelers who canceled flights during the pandemic extra time to rebook, but some expiration dates loom to the dismay of travelers.
The airline has announced or begun flights to 17 new destinations since the coronavirus pandemic began a year ago.
Poem of the week: The rain in the night by Heidi WilliamsonThe enduring grief of the Dunblane primary school massacre in Scotland, 25 years ago, is discreetly and powerfully portrayed ‘It wasn’t there, then it was / all around the house’ … a general view of Dunblane Cathedral. Photograph: Andrew Milligan/PA
'It's incomparable' – Rangers fans' journey from Brechin to another title. Supporters, many of whom feared their club might go under, share their thoughts after a first league title in 10 years
In December 2020, Opendoor (NASDAQ: OPEN) completed its IPO via SPAC, raising net proceeds of $970 million. Although Opendoor is new to the public market, it was one of the first iBuyers promising homeowners an instant cash offer for their properties and allowing them to bypass the traditional home sales process. Total revenue was $2.58 billion, as compared to $4.74 billion in 2019.
"For all the racist comments, we continue to laugh," Sanches, who claimed an assist for the French Ligue 1 leaders, wrote on Instagram. The slur refers to the slave trade between the 15th and 19th centuries when African men, women and children endured a life of subjugation on cotton plantations. Elsewhere, Algerian winger Adam Ounas also revealed he had received racist abuse on social media after he scored a goal and assisted another in Crotone's 4-2 Serie A win over Torino on Sunday.
Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)MALVERN Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the appointment of Richard S. Casten, CPA, MBA as Chief Financial Officer. In this role, Mr. Casten will be responsible for leading and directing the financial activities of the Company. Mr. Casten brings to Baudax 25 years of diversified financial experience across pharmaceutical, Fortune 500 consumer products and public accounting. He replaces Ryan D. Lake, CPA who is transitioning to full time Chief Financial Officer for Recro. “I am delighted to welcome Richard to the Baudax team and believe his expertise and leadership skills will be critically important to us as we continue to execute on the commercial rollout of ANJESO® in the U.S. and pursue our ongoing growth initiatives,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. “Richard is a proven leader in our industry and his extensive financial experience will be a valuable addition to the Company.” Ms. Henwood continued, “The Board and I wish to express our sincere gratitude to Ryan for his many contributions and service and wish him well in his role as full time Chief Financial Officer at Recro.” Mr. Casten commented: “Baudax is an exciting growth story and an emerging leader in the acute care setting. The team has been making great strides since its launch toward bringing ANJESO to patients in the U.S. and I am pleased to be joining at such a pivotal time. I look forward to working with the entire leadership team and contributing to the Company’s future success.” Prior to joining Baudax, Mr. Casten served as Vice President of Finance, Controller and Treasurer at Lupin Pharmaceuticals, Inc. Previous to Lupin, Mr. Casten served in roles of increasing responsibility at Endo International plc, culminating in his role as Senior Director, Financial Planning and Analysis. Prior to Endo, he served in various financial roles at the Campbell Soup Company. Mr. Casten spent the initial ten years of his career in public accounting, with eight years at Ernst & Young LLP, rising to a Senior Manager, Assurance and Advisory Business Services, and at Fishbein & Company as an Assurance Staff Accountant. He holds a Bachelor of Science in Business and Economics, with a major in Accounting, from Lehigh University and a Master’s in Business Administration from the Johnson School at Cornell University. Mr. Casten is a Certified Public Accountant in both Pennsylvania and California and is a member of American and Pennsylvania Institute of Certified Public Accountants. Inducement Grant under NASDAQ Listing Rule 5635(c)(4) In connection with the hiring of Mr. Casten, the Compensation Committee of Baudax Bio’s Board of Directors approved an inducement grant of stock options to purchase an aggregate of 270,000 shares of Baudax Bio’s common stock and restricted stock units covering 100,000 shares of Baudax Bio’s common stock, with a grant date of March 8, 2021. The equity award was granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of Mr. Casten’s employment compensation and was granted as an inducement material to his acceptance of employment with Baudax Bio. The options have an exercise price equal to the closing price of Baudax Bio’s common stock as reported by Nasdaq on March 8, 2021. The options have a ten-year term and vest over four years, with 25% of the number of shares underlying the stock option vesting on the one-year anniversary of the grant date and the remaining shares vesting monthly over 36 months thereafter. The restricted stock units vest annually over four years. The equity award is subject to Mr. Casten’s continued service with Baudax Bio through the applicable vesting dates. About ANJESO® ANJESO (meloxicam) injection is a proprietary, long-acting, preferential COX-2 inhibitor that possesses analgesic, anti-inflammatory and antipyretic activities, which are believed to be related to the inhibition of cyclooxygenase type 2 pathway (COX-2) and subsequent reduction in prostaglandin biosynthesis. ANJESO was launched in the U.S. in June 2020 following its approval by the Food and Drug Administration in February 2020. ANJESO is indicated for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. Because of the delayed onset of analgesia, ANJESO alone is not recommended for use when rapid onset of analgesia is required. ANJESO is supported by two pivotal Phase III clinical efficacy trials, a large double-blind, placebo-controlled Phase III safety trial and four Phase II clinical efficacy trials, as well as other safety studies. As a non-opioid, Baudax Bio believes ANJESO has the potential to overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, constipation, excessive nausea and vomiting, as well as having no addictive potential, while maintaining meaningful analgesic effects for relief of pain. ANJESO was designed using the NanoCrystal® platform, a technology that enables enhanced bioavailability of poorly water-soluble drug compounds. NanoCrystal® is a registered trademark of Alkermes Pharma Ireland Limited (APIL). About Baudax Bio Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The launch of Baudax Bio’s first commercial product ANJESO® began in June 2020 following its approval by the U.S. Food and Drug Administration in February 2020. ANJESO is a once daily IV NSAID with preferential Cox-2 activity, which has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other studies for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other pharmaceutical assets including two novel neuromuscular blocking agents (NMBAs) and a proprietary chemical reversal agent specific to these NMBAs which is currently in preclinical studies, and intranasal dexmedetomidine which is being developed for possible uses in pain or sedation. For more information, please visit www.baudaxbio.com. Cautionary Statement Regarding Forward Looking Statements This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio as of the date of publication on this internet site and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These forward-looking statements are subject to risks and uncertainties including, among other things, the ongoing economic and social consequences of the COVID-19 pandemic, including any adverse impact on the commercial launch of ANJESO® or disruption in supply chain, Baudax Bio’s ability to maintain regulatory approval for ANJESO, Baudax Bio’s ability to successfully commercialize ANJESO; the acceptance of ANJESO by the medical community, including physicians, patients, health care providers and hospital formularies; Baudax Bio’s ability and that of Baudax Bio’s third party manufacturers to successfully scale-up our commercial manufacturing process for ANJESO, Baudax Bio’s ability to produce commercial supply in quantities and quality sufficient to satisfy market demand for ANJESO, Baudax Bio’s ability to raise future financing for continued product development, payment of milestones and ANJESO commercialization, Baudax Bio’s ability to pay its debt and satisfy conditions necessary to access future tranches of debt, Baudax Bio’s ability to comply with the financial and other covenants under its credit facility, Baudax Bio’s ability to manage costs and execute on our operational and budget plans, the accuracy of Baudax Bio’s estimates of the potential market for ANJESO, Baudax Bio’s ability to achieve its financial goals; and Baudax Bio’s ability to obtain, maintain and successfully enforce adequate patent and other intellectual property protection. These forward-looking statements should be considered together with the risks and uncertainties that may affect our business and future results included in our filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to us, and we assume no obligation to update any forward-looking statements except as required by applicable law. CONTACT: Investor Relations Contact:Argot PartnersSam Martin / Claudia Styslinger(212) firstname.lastname@example.org Media Contact:Argot PartnersDavid Rosen(212) email@example.com
Rockwell Automation (NYSE: ROK) Chairman and CEO, Blake Moret, and SVP and Chief Financial Officer, Nick Gangestad, will present at J.P. Morgan Industrials Conference on Monday, March 15, 2021.
Figure 1 Bousquet Property Location MONTREAL, March 08, 2021 (GLOBE NEWSWIRE) -- Bullion Gold Resources Corp. (TSX-V: BGD) (“Bullion Gold” or the “Corporation”) is pleased to announce that it has entered into an Option Agreement (the “Agreement”) with Vantex Resources Ltd. (“Vantex”) to acquire up to 100% of the Bousquet Property (the “Property”) located on the historical Cadillac Break. The Property consists of two claim blocks totalling 70 claims covering 1515.55 ha. The Bousquet property is in the Abitibi Region of the Province of Québec, about 30 kilometers west of Rouyn-Noranda. The Bousquet Property is underlain by meta-sedimentary rocks of the Cadillac, Timiskaming and Pontiac Groups and from volcanic flows and intrusives of the Piche Group. The Cadillac-Larder Lake Break crosses the property for 2.5 km in the northern part of the Normar Block. There are several gold mines found along or adjacent to the Cadillac-Larder Lake Break that cuts across the Bousquet Lake Property. Between 1926 and 2020, in excess of twenty (20) mines have produced over 25 million ounces of gold along the Cadillac Break within the Bousquet-Cadillac district. The Cadillac mining camp is characterized by three types of mineralization related to distinct gold-bearing geological settings: gold-bearing massive sulphide lenses (Bousquet 2 and La Ronde mines), gold-rich polymetallic veins (Doyon and Mouska mines) and auriferous veins associated with regional E-W trending faults (Lapa deposit). A strong gold mineralized system was discovered in the southern portion of the Bousquet Lake Property. Three gold showings, Decoeur, Paquin East and Paquin West and Calder-Bousquet, were discovered in the early exploration work (1932-1945) on the property. These showings have probably been formed in the same mineralizing episode within regional E-W trending faults. On the Decoeur showing, grades of 8.40 g/t Au over 1.77 m, 4.35 g/t Au over 4.83 and 4.04 g/t Au over 1.52 m were intersected in historical drill holes. On the Paquin showings, 3.73 g/t Au over 5.49 m, 5.91 g/t Au over 3.02 m and 6.84 and 6.53 g/t Au over 2.44 m were intersected in historical drilling. An intercept of 8.09 g/t Au over 2.0 m was also intersected on the Calder-Bousquet gold occurrence. The gold mineralization is located in a fold zone above the 250m level. Strong possibilities exist that other folds from the same deformation exist laterally or at depth. The Blackfly group of claims has been little explored in the past due to the paucity of outcrops but the use of new geophysical methods can generate good and valid targets from the deposit models of this high quality location within one of the most prolific world class gold belt. Gold mineralization was also found in a 2003 drill program in the felsic intrusion (called tonalite) within the Cadillac fault zone. The intrusive is found between two talc-chlorite schist units of the Piche Group. Hole TMN-03-31 intersected 4.75 g/t Au over 1.5 m in quartz veins, veinlets, and zones of silicification and hole TMN-03-08 intersected 1.42 g/t Au over 1.5 m and 0.71 g/t Au over 5.7 m gold also in the tonalite. “We are incredibly pleased with this option agreement, which positions us strategically on the Cadillac Fault, a globally recognized gold producing environment. We were attracted by the Property due to the interesting historical showings (Paquin Est, Paquin Ouest and Decoeur) and by the fact that these showings remain open both laterally and at depth. To our knowledge, no depth survey (more than 250 meters) has been carried out on the property.” Said Jonathan Hamel, President and CEO of Bullion Gold Resources Corp. Terms of Agreement Under the terms of the Agreement, the Company may earn a 100% interest in seventy-eight (78) claims forming The Property by satisfying the following conditions, subject to TSX Venture Exchange approval: I. paying to Vantex a total of $150,000 as follows: $30,000 upon the TSX Venture Exchange Approval (The “Effective Date”);a further $30,000 on or before the 3th month anniversary of the Effective Date;a further $30,000 on or before the 6th month anniversary of the Effective Date;a further $30,000 on or before the 9th month anniversary of the Effective Date; anda final $30,000 on or before the 12th month anniversary of the Effective Date. II. allotting and issuing to Vantex, as fully paid and non-assessable, a total of 1,250,000 Shares as follows: 500,000 upon the Effective Date;a further 375,000 on or before the 6th month anniversary of the Effective Date; anda final 375,000 on or before the 9th month anniversary of the Effective Date. Vantex owns a 100% interest in the 52 claims of the Blackfly block and owns a 60% interest in the Normar block (18 claims), the other 40% belongs to Nyrstar N.V. from Switzerland. There are various royalty obligations on the mining claims. Mr. Gilles Laverdière. P.Geo, director and qualified person under NI 43-101 has read and approved this press release. About Bullion Gold Bullion Gold is involved in the identification, exploration and development of viable mineral properties in the Province Quebec and British Columbia. For more information on the Corporation, visit www.bulliongold.ca For further information, please contact: Jonathan HamelPresident and CEOjhamel@bulliongold.ca514-531-8129 Other Information The TSX Venture Exchange and its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts no responsibility for the veracity or accuracy of its content. Forward-Looking Statements: This press release contains forward-looking statements. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", “anticipate", "estimate", "may", "will", "would", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. The forward-looking statements are based on certain key expectations and assumptions made by the Corporation. Although Bullion Gold believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Bullion Gold can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. In addition to other risks that may affect the forward-looking statements in this press release are those set out in the Corporation’s management discussion and analysis of the financial condition and results of operations for the year ended December 31, 2019 and the third quarter ended September 30, 2020, which are available on the Corporation’s profile at www.sedar.com. The forward-looking statements contained in this press release are made as of the date hereof and Warrior Gold undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. A figure accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3d7c2fb1-10e3-4feb-9368-57e1af2b6187
Belluscura plc announced the receipt of 510(k) Clearance from the US Food and Drug Administration (the “FDA”) for its X-PLO2R™, Portable Oxygen Concentrator LONDON, UNITED KINGDOM , March 08, 2021 (GLOBE NEWSWIRE) -- Tekcapital Plc (AIM: TEK), (OTCQB: TEKCF), the UK intellectual property investment group focused on creating valuable products from investing in university technology, announces that its portfolio company Belluscura plc has been granted 510(k) clearance and marketing authorisation by the U.S. Food and Drug Administration (FDA) for the X-PLO2R POC portable oxygen concentrator (POC). Belluscura developed the X-PLO2R POC with their research partner, Separation Design Group, an award-winning oxygen enrichment research laboratory. The X-PLO2R POC has patented technology that can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week. Weighing less than 3.25 lbs. (1.5 kg), the lightweight X-PLO2R POC is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as the Chronic Obstructive Pulmonary Disease (COPD) and respiratory distress caused by COVID-19. The X-PLO2R is expected to be commercially launched in 2021. This is a transformative development for Belluscura. Belluscura has exclusively licensed, acquired or jointly invented 18 patents and applications in the field of concentrated oxygen generation. According to Global Market Insights, the medical portable O2 market is expected to grow from $1.6bn in 2018 to US $2.4bn by 2025 with a CAGR of 8%.¹ Belluscura also confirms that it is considering the feasibility and timing of an initial public offering (IPO), and the potential admission to trading on the AIM Market of the London Stock Exchange (or other recognised stock exchange) and expects investments should qualify for Enterprise Investment Scheme (EIS) relief. Tekcapital owns approximately 17.8% (10.5m shares) of Belluscura. From previous investments made by Tekcapital in Belluscura, Tekcapital holds warrants to purchase 1,273,078 shares at 13p and 600,000 shares at 15p. Additionally, concomitant with Belluscura’s receipt of FDA Clearance, Tekcapital has 30 days to exercise an option to purchase up to approximately 4.8m Belluscura shares between 21p - 23p depending upon amount invested. If all warrants and options are exercised, than Tekcapital would hold approximately 17.1m shares in Belluscura. Clifford M. Gross Ph.D., Executive Chairman of Tekcapital plc commented: "We are excited to see that the FDA has cleared the X-PLO2R device for sale, as Tekcapital and Belluscura believe it could be helpful to patients during the COVID-19 pandemic, and for many of the 250 million people worldwide suffering from chronic obstructive pulmonary disease (COPD)2. Our congratulations to Robert Rauker and his capable team at Belluscura for a job well done!” About Belluscura plc Belluscura (www.belluscura.com) is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organizations. About Tekcapital plc Tekcapital creates value from investing in new, university-developed discoveries that can enhance people’s lives and provides a range of technology transfer services to help organisations evaluate and commercialise new technologies. Tekcapital is quoted on the AIM market of the London Stock Exchange (AIM: symbol TEK) and is headquartered in the UK. For more information, please visit www.tekcapital.com Forward Looking Statements & DisclaimerThis press release is for informational purposes only. The information herein does not constitute investment advice nor an offer to invest and may contain statements related to our future business and financial performance and future events or developments involving Tekcapital that may constitute forward-looking statements. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. We may also make forward-looking statements in other reports, in presentations, on social media, in material delivered to customers, stakeholders and in press releases. In addition, our representatives may from time to time make oral forward-looking statements. Such statements may be based on the current expectations and certain assumptions of Tekcapital’s management. Please note that these are subject to a number of risks, uncertainties and factors, including, but not limited to those described in various disclosures. Should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of Tekcapital may vary materially from those described explicitly or implicitly in the relevant forward-looking statement. Forward-looking statements express, as at the date of this release, the Company’s plans, estimates, valuations, forecasts, projections, opinions, expectations or beliefs as to future events, results or performance. Forward-looking statements involve a number of risks and uncertainties, many of which are beyond the Company’s control, including those associated with COVID-19, and there can be no assurance that such statements will prove to be accurate. No assurance is given that such forward looking statements or views are correct or that the objectives of the Company will be achieved. Further, valuations of Company’s portfolio investments and net asset value can and will fluctuate over time due to a variety of factors and this could have a material negative impact on the Company’s financial performance. Tekcapital neither intends, nor assumes any obligation, to update or revise these forward-looking statements in light of developments which may differ from those anticipated. References https://www.gminsights.com/industry-analysis/medical-oxygen-concentrators-market-reporthttps://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd) CONTACT: Tekcapital Plc Via Flagstaff Clifford M. Gross, Ph.D. SP Angel Corporate Finance LLP (Nominated Adviser and Broker)+44 (0) 20 3470 0470 Richard Morrison/Charlie Bouverat (Corporate Finance) Abigail Wayne / Rob Rees (Corporate Broking) Flagstaff Strategic and Investor Communications (U.K.)+44 (0) 20 7129 1474 Skyline Corporate Communications Group, LLC (U.S.) Matthew Abenante/Scott Powell +1 646 893 5835
ArsenalBio, a privately held programmable cell therapy company, today announced the expansion of its leadership team with the appointments of John Schroer, CFA as Chief Financial Officer (CFO) and Tim Sirichoke as Chief Technical Operations Officer (CTOO). Mr. Schroer previously served as CFO at Translate Bio and Managing Director and Healthcare Sector Head at Allianz Global Investors. Mr. Sirichoke will be responsible for all aspects of manufacturing for the company, drawing on his previous roles and responsibilities as Vice President, Manufacturing at Genentech, a Member of the Roche Group, and Kite Pharma, a Gilead company.